

GARDP's pipeline (April 2022)

DISCOVERY	DISEASE AREA	TRANSLATIONAL	DEVELOPMENT		REGULATORY	IMPLEMENTATION
		Pre-clinical / Early Clinical	Pediatric trials	Phase 3	Registration Status	Access Development
AMR Screening Consortium Eisai, Takeda & Daiichi S. Antibiotic potentiators Calibr / Scripps Natural Products HIPS	SERIOUS BACTERIAL INFECTIONS	Potential candidate A (NCE or repurposed)	Cefiderocol*** Neonatal PIP / PSP	Cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals**	Cefiderocol (Shionogi)*** Approved USA / EU	Access strategy Access opportunity
	CHILDREN'S ANTIBIOTICS	IV Fosfomycin	Treatment regimens Public health strategic efficacy and safety trials		Approved in EU, with Neo & Paeds label	
		Flomoxef			Approved in Asia: Neo & Paeds data	
	Amikacin	Approved globally: Neo & Paeds data				
	PAEDIATRIC DEVELOPMENT	Polymyxin B*	Regulatory paediatric plans (serious bacterial infections paediatric and neonates)		Approved in USA, with limited Neo & Paeds label	
		Paediatric cefepime-taniborbactam (NCE) Venatorx Pharmaceuticals				
	SEXUALLY TRANSMITTED INFECTIONS	Potential candidate A (NCE or repurposed)		Zoliflodacin (NCE) Entasis Therapeutics Inc.		Access strategy Including manufacturing development
		Potential candidate B (NCE)				Surveillance / Prevalence studies
					Approved in USA / EU for CABP	

* Under review / on-hold

** Development of cefepime-taniborbactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom

*** Potential pipeline addition, MOU signed between GARDP, Shionogi and Clinton Health Access Initiative (CHAI) to explore Cefiderocol access in LMICs